key: cord-0773726-l1kettn5 authors: Akkaoui, Marine Ambar; Lejoyeux, Michel; Geoffroy, Pierre A. title: Chloroquine-induced first-episode psychosis in a patient self-medicated for covid-19 date: 2020-06-02 journal: Biol Psychiatry DOI: 10.1016/j.biopsych.2020.05.032 sha: fe702ebcb2ae4bd880aa9bba9599df3511941789 doc_id: 773726 cord_uid: l1kettn5 nan with worldwide controversies (1) (2) (3) , leading to an increase in its use, including frequent selfmedications. Some studies examined the safety of HCQ in the treatment of COVID-19 (2), but none reported potential psychiatric side-effects. We report here the case of a first-episode psychosis in a patient self-medicated with chloroquine (CQ) for COVID-19. A 57-year-old woman was accompanied by firefighters to the emergency room (ER) at Bichat hospital in Paris, France, for a major psychomotor agitation. This patient had never been hospitalized in psychiatry, nor had similar episodes. Her general practitioner prescribed ESCITALOPRAM 10mg/day since several years for subsyndromal anxiety. She had no other personal or family medical history. Her son lives with her and developed symptoms evocating a Covid-19 infection three weeks earlier. Afraid about getting the Covid-19, the patient self-medicated for 7 days to prevent it with Chloroquine. After 2 days, the patient presented with agitation and aggressiveness. The morning of the seventh day, she left the house shouting and slamming the door, and was found few hours later in the street in a state of major psychomotor agitation. On her arrival at the ER, the patient still suffered from agitation, with mystical delusion and visual hallucinations, associated with severe anxiety. Sedation with LOXAPINE 100 mg and CLONAZEPAM 1mg was administered with a mechanical contention. Complementary examinations, brain scan and standard blood exams were normal. We estimated the probability of psychiatric adverse drug reactions with the Naranjo algorithm, which confirmed CQ imputability as "probable" (Total score=7; previous conclusive reports on this reaction (+1), psychotic symptoms appeared after CQ was introduced (+2), symptoms disappeared after CQ was discontinued (+1), no alternative cause of the symptoms (+2), symptoms were confirmed by standardized examination (+1)). The patient was hospitalized in a psychiatric department. In this first report of Chloroquine-induced first-episode psychosis in a patient self-medicated for covid-19, we should remind that psychosis and mood disorders are among the most frequent psychiatric adverse effects of CQ (4). Moreover, CQ is metabolized by the cytochrome 2D6 (CYP2D6), and the CQ toxicity may have been enhanced here by ESCITALOPRAM, which is a CYP2D6 inhibitor(5). In conclusion, Chloroquine may induce de novo psychotic symptoms. This report highlights the risks of self-medication with CQ and the need for a close monitoring of psychiatric symptoms. Particular attention might be required with co-prescriptions of CYP2D6 inhibitors. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy Authors' contributions: All authors have contributed to and approved the submitted draft manuscript. All authors report no biomedical financial interests or potential conflicts of interest.Role of funding source and ethics committee approval: Not applicable.